Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

@article{Nanus2003ClinicalUO,
  title={Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.},
  author={David M. Nanus and Matthew Ivan Milowsky and Lale Kostakoglu and Peter M. Smith-Jones and Shankar Vallabahajosula and Stanley J. Goldsmith and Neil Harrison Bander},
  journal={The Journal of urology},
  year={2003},
  volume={170 6 Pt 2},
  pages={S84-8; discussion S88-9}
}
PURPOSE Prostate specific membrane antigen (PSMA) is a cell surface peptidase highly expressed by malignant prostate epithelial cells and vascular endothelial cells of numerous solid tumor malignancies but not normal vascular endothelium in benign tissues or neoplastic epithelial cells of nonprostate malignancies. Monoclonal antibody (mAb) J591 recognizes the extracellular domain of PSMA. The current status of clinical trials using mAb J591 is reviewed. MATERIAL AND METHODS The mouse antibody… CONTINUE READING